2.00
0.00
(0.00%)
May 21 - Close
NASDAQ
real-time data -
Disclaimer
Currency in USD
| Range | - |
| 52 week | 1.71 - 6.24 |
| Open | - |
| Vol / Avg. | 0.00/1.14M |
| Mkt cap | 114.43M |
| P/E | - |
| Div/yield | - |
| EPS | -0.38 |
| Shares | 57.22M |
| Beta | 1.84 |
| Inst. own | 53% |
Events
Aug 7, 2013
Q2 2013 Oncothyreon Inc. Earnings Release
Jun 13, 2013
Oncothyreon Inc. Annual Shareholder Meeting
- 12:00PM EDT -
May 16, 2013
Oncothyreon Inc. at Bank of America Merrill Lynch Health Care Conference
May 9, 2013
Q1 2013 Oncothyreon Inc. Earnings Conference Call
May 9, 2013
Q1 2013 Oncothyreon Inc. Earnings Release
Apr 5, 2013
Oncothyreon Inc. at BioCentury Publications Future Leaders in the Biotech Industry Conference
Mar 14, 2013
Q4 2012 Oncothyreon Inc. Earnings Conference Call
Mar 6, 2013
Oncothyreon Inc. at Cowen Health Care Conference
|
More events from DailyFinance »
|
Key stats and ratios
| Q1 (Mar '13) | 2012 | |
| Net profit margin | - | - |
| Operating margin | - | - |
| EBITD margin | - | - |
| Return on average assets | -38.72% | -4.24% |
| Return on average equity | -42.40% | -5.90% |
| Employees | 42 | - |
| Carbon Disclosure Rating | - | - |
Address
Suite 500, 2601 Fourth Avenue
SEATTLE, WA 98121
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)
SEATTLE, WA 98121
United States - Map
+1-206-8012100 (Phone)
+1-206-8012101 (Fax)
Website links
External links
Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Research Reports - Reuters
Discussion Group - Google Finance
Volume delayed by 15 mins.
Advertisement
Description
Oncothyreon Inc. (Oncothyreon) is a clinical-stage biopharmaceutical company focused primarily on the development of therapeutic products for the treatment of cancer. The Company�s cancer vaccines are designed to stimulate the immune system to attack cancer cells, while its small molecule compounds are designed to inhibit the activity of specific cancer-related proteins. Its lead product candidate, Stimuvax, is a cancer vaccine being evaluated in two Phase III clinical trials for the treatment of non-small cell lung cancer (NSCLC). It has granted worldwide license to Merck KGaA of Darmstadt, Germany (Merck KGaA), for the development, manufacture and commercialization of Stimuvax. Merck KGaA has completed enrollment of 1514 patients in the Phase III START trial of Stimuvax in NSCLC.
Officers and directors
| Robert L. Kirkman M.D. | President, Chief Executive Officer, Director | |
| Julia Marie Eastland | Chief Financial Officer, Vice President - Corporate Development, Secretary | |
| Gary Christianson | Chief Operating Officer | |
| Scott Peterson Ph.D. | Chief Scientific Officer, Vice President - Research & Development | |
| Diana Hausman M.D. | Chief Medical Officer, Vice President - Clinical Development | |
| Christopher S. Henney Ph.D. | Non-Executive Independent Chairman of the Board | |
| Richard L. Jackson Ph.D. | Independent Director | |
| Daniel K. Spiegelman | Independent Director | |
| W. Vickery Stoughton | Independent Director | |
| Douglas E. Williams Ph.D. | Independent Director |